Biologics Market Research Report - Forecast to 2030

Biologics Market Research Report: By Product (Monoclonal Antibody, Interleukins, Vaccines, Growth Factors, Gene Therapy, Others), By Disease Indication (Rheumatoid Arthritis, Psoriasis/Psoriatic Arthritis, Cancer, Diabetes, Others), By Manufacturing (In-house, Sourced) - Forecast to 2030

ID: MRFR/HC/0831-CR | December 2018 | Region: Global | 138 Pages         

1 Report Prologue

2 Market Introduction

2.1 Introduction 15

2.2 Scope Of The Study 15

2.3 Assumptions & Limitations 15

3 Research Methodology

3.1 Research Process 18

3.2 Primary Research 19

3.3 Secondary Research 20

3.4 Market Size Estimation 21

3.5 Forecast Model 21

4 Market Dynamics

4.1 Introduction 23

4.2 Drivers 23

4.2.1 Increasing Healthcare Expenditure 23

4.2.2 Advancements In Biologics 24

4.2.3 Rising Prevalence Of Chronic And Acute Diseases 24

4.3 Restraints 24

4.3.1 Emergence Of Biosimilars 24

4.3.2 Adverse Effects Of Biologic Drugs 24

4.4 Opportunities 25

4.4.1 Strong Pipeline For Biologic Drugs 25

5 Market Factor Analysis

5.1 Value/Supply Chain Analysis 27

5.1.1 Research & Development 27

5.1.2 Raw Material 27

5.1.3 Manufacturer 27

5.1.4 Distributor 28

5.1.5 Customer 28

5.1.6 Consumer 28

5.2 Porterโ€™s Five Force Analysis 29

5.2.1 Threat From A New Entrant 30

5.2.2 Bargaining Power Of Buyer 30

5.2.3 Bargaining Power Of Supplier 30

5.2.4 Threat From Substitute 31

5.2.5 Rivalry 31

5.3 Investment Opportunity Analysis 32

5.3.1 Investment Risks 32

5.3.2 Market Outlook 32

5.4 Pricing Analysis 32

6 Biologics Market, By Product

6.1 Overview 34

6.2 Monoclonal Antibody 35

6.2.1 Humanized 36

6.2.2 Human 36

6.2.3 Chimeric 36

6.2.4 Murine 37

6.3 Interleukins 37

6.4 Vaccines 38

6.5 Growth Factors 39

6.6 Gene Therapy 39

7 Biologics Market, By Disease Indication

7.1 Overview 41

7.2 Cancer 42

7.3 Rheumatoid Arthritis 43

7.4 Psoriasis/ Psoriatic Arthritis 44

7.5 Diabetes 45

7.6 Ankylosing Spondylitis 45

7.7 Ulcerative Colitis 46

7.8 Crohn's Disease 46

7.9 Juvenile Idiopathic Arthropathy 47

7.10 Cardiovascular Diseases 48

8 Biologics Market, By Manufacturing

8.1 Overview 50

8.2 In-House 51

8.3 Outsourced 51

9 Global Biologics Market, By Region

9.1 Overview 53

9.2 Americas 54

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.2.1 North America 57

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.2.1.1 US 59

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.2.1.2 Canada 61

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.2.2 South America 63

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.3 Europe 65

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.3.1 Western Europe 68

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.3.1.1 Germany 71

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.3.1.2 France 73

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.3.1.3 UK 75

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.3.1.4 Italy 77

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.3.1.5 Spain 79

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.3.1.6 Rest Of Western Europe 81

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.3.2 Eastern Europe 83

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.4 Asia-Pacific 85

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.4.1 Japan 88

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.4.2 China 90

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.4.3 India 92

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.4.4 Australia 94

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.4.5 South Korea 96

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.4.6 Rest Of Asia-Pacific 98

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.5 Middle East & Africa 100

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.5.1 Middle East 103

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

9.5.2 Africa 105

Biologics Market, By Product

Biologics Market, By Disease Indication

Biologics Market, By Manufacturing

10 Competitive Landscape

10.1 Company Market Share Analysis 108

10.2 Competitive Scenario 109

11 Company Profiles

11.1 AbbVie, Inc. 111

11.1.1 Company Overview 111

11.1.2 Financial Overview 111

11.1.3 Products/Services Offering 112

11.1.4 Key Developments 112

11.1.5 SWOT Analysis 112

11.1.6 Key Strategy 112

11.2 Pfizer Inc. 113

11.2.1 Company Overview 113

11.2.2 Financial Overview 113

11.2.3 Products/Services Offering 114

11.2.4 Key Developments 114

11.2.5 SWOT Analysis 115

11.2.6 Key Strategy 115

11.3 AstraZeneca 116

11.3.1 Company Overview 116

11.3.2 Financial Overview 116

11.3.3 Products/Services Offering 117

11.3.4 Key Developments 117

11.3.5 SWOT Analysis 117

11.3.6 Key Strategy 117

11.4 Novartis AG 118

11.4.1 Company Overview 118

11.4.2 Financial Overview 118

11.4.3 Products Offering 119

11.4.4 Key Developments 119

11.4.5 SWOT Analysis 119

11.4.6 Key Strategy 119

11.5 F. Hoffmann-La Roche AG 120

11.5.1 Company Overview 120

11.5.2 Financial Overview 120

11.5.3 Products Offering 121

11.5.4 Key Developments 121

11.5.5 SWOT Analysis 121

11.5.6 Key Strategy 121

11.6 Bayer AG 122

11.6.1 Company Overview 122

11.6.2 Financial Overview 122

11.6.3 Products Offering 123

11.6.4 Key Developments 123

11.6.5 SWOT Analysis 123

11.6.6 Key Strategy 124

11.7 Amgen 125

11.7.1 Company Overview 125

11.7.2 Financial Overview 125

11.7.3 Products Offering 126

11.7.4 Key Developments 126

11.7.5 SWOT Analysis 126

11.7.6 Key Strategy 127

11.8 Sanofi 128

11.8.1 Company Overview 128

11.8.2 Financial Overview 128

11.8.3 Products Offering 129

11.8.4 Key Developments 129

11.8.5 SWOT Analysis 129

11.8.6 Key Strategy 129

11.9 Eli Lilly And Company 130

11.9.1 Company Overview 130

11.9.2 Financial Overview 130

11.9.3 Products Offering 131

11.9.4 Key Developments 131

11.9.5 SWOT Analysis 131

11.9.6 Key Strategy 131

11.10 GlaxoSmithKline Plc (GSK) 132

11.10.1 Company Overview 132

11.10.2 Financial Overview 132

11.10.3 Products Offering 133

11.10.4 Key Developments 133

11.10.5 SWOT Analysis 133

11.10.6 Key Strategy 134

12 Appendix

12.1 Discussion Blue Print 136

13 List Of Tables

TABLE 1 GLOBAL BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 34

TABLE 2 GLOBAL BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY REGION, 2020 TO 2027 (USD MILLION) 35

TABLE 3 GLOBAL BIOLOGICS MARKET FOR INTERLEUKINS BY REGION, 2020 TO 2027 (USD MILLION) 36

TABLE 4 GLOBAL BIOLOGICS MARKET FOR HUMAN BY REGION, 2020 TO 2027 (USD MILLION) 36

TABLE 5 GLOBAL BIOLOGICS MARKET FOR CHIMERIC BY REGION, 2020 TO 2027 (USD MILLION) 36

TABLE 6 GLOBAL BIOLOGICS MARKET FOR MURINE BY REGION, 2020 TO 2027 (USD MILLION) 37

TABLE 7 GLOBAL BIOLOGICS MARKET FOR INTERLEUKINS BY REGION, 2020 TO 2027 (USD MILLION) 37

TABLE 8 GLOBAL BIOLOGICS MARKET FOR VACCINES BY REGION, 2020 TO 2027 (USD MILLION) 38

TABLE 9 GLOBAL BIOLOGICS MARKET FOR GROWTH FACTORS BY REGION, 2020 TO 2027 (USD MILLION) 39

TABLE 10 GLOBAL BIOLOGICS MARKET FOR GENE THERAPY BY REGION, 2020 TO 2027 (USD MILLION) 39

TABLE 11 GLOBAL BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 41

TABLE 12 GLOBAL BIOLOGICS MARKET FOR CANCER BY REGION, 2020 TO 2027 (USD MILLION) 42

TABLE 13 GLOBAL BIOLOGICS MARKET FOR RHEUMATOID ARTHRITIS BY REGION, 2020 TO 2027 (USD MILLION) 43

TABLE 14 GLOBAL BIOLOGICS MARKET FOR PSORIASIS/ PSORIATIC ARTHRITIS BY REGION, 2020 TO 2027 (USD MILLION) 44

TABLE 15 GLOBAL BIOLOGICS MARKET FOR DIABETES BY REGION, 2020 TO 2027 (USD MILLION) 45

TABLE 16 GLOBAL BIOLOGICS MARKET FOR ANKYLOSING SPONDYLITIS BY REGION, 2020 TO 2027 (USD MILLION) 45

TABLE 17 GLOBAL BIOLOGICS MARKET FOR ULCERATIVE COLITIS BY REGION, 2020 TO 2027 (USD MILLION) 46

TABLE 18 GLOBAL BIOLOGICS MARKET FOR CROHN'S DISEASE BY REGION, 2020 TO 2027 (USD MILLION) 46

TABLE 19 GLOBAL BIOLOGICS MARKET FOR JUVENILE IDIOPATHIC ARTHROPATHY BY REGION, 2020 TO 2027 (USD MILLION) 47

TABLE 20 GLOBAL BIOLOGICS MARKET FOR CARDIOVASCULAR DISEASES BY REGION, 2020 TO 2027 (USD MILLION) 48

TABLE 21 GLOBAL BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 50

TABLE 22 GLOBAL BIOLOGICS MARKET FOR IN-HOUSE BY REGION, 2020 TO 2027 (USD MILLION) 51

TABLE 23 GLOBAL BIOLOGICS MARKET FOR OUTSOURCED BY REGION, 2020 TO 2027 (USD MILLION) 51

TABLE 24 GLOBAL BIOLOGICS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 53

TABLE 25 AMERICAS BIOLOGICS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 54

TABLE 26 AMERICAS BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 55

TABLE 27 AMERICAS BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 55

TABLE 28 AMERICAS BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 56

TABLE 29 AMERICAS BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 56

TABLE 30 NORTH AMERICA BIOLOGICS MARKET BY COUNTRY, 2020 TO 2027 (USD MILLION) 57

TABLE 31 NORTH AMERICA BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 57

TABLE 32 NORTH AMERICA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 58

TABLE 33 NORTH AMERICA BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 58

TABLE 34 NORTH AMERICA BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 58

TABLE 35 US BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 59

TABLE 36 US BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 59

TABLE 37 US BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 60

TABLE 38 US BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 60

TABLE 39 CANADA BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 61

TABLE 40 CANADA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 61

TABLE 41 CANADA BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 62

TABLE 42 CANADA BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 62

TABLE 43 SOUTH AMERICA BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 63

TABLE 44 SOUTH AMERICA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 63

TABLE 45 SOUTH AMERICA BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 64

TABLE 46 SOUTH AMERICA BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 64

TABLE 47 EUROPE BIOLOGICS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 65

TABLE 48 EUROPE BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 66

TABLE 49 EUROPE BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 66

TABLE 50 EUROPE BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 67

TABLE 51 EUROPE BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 67

TABLE 52 WESTERN EUROPE BIOLOGICS MARKET BY COUNTRY, 2020 TO 2027 (USD MILLION) 68

TABLE 53 WESTERN EUROPE BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 69

TABLE 54 WESTERN EUROPE BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 69

TABLE 55 WESTERN EUROPE BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 70

TABLE 56 WESTERN EUROPE BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 70

TABLE 57 GERMANY BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 71

TABLE 58 GERMANY BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 71

TABLE 59 GERMANY BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 72

TABLE 60 GERMANY BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 72

TABLE 61 FRANCE BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 73

TABLE 62 FRANCE BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 73

TABLE 63 FRANCE BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 74

TABLE 64 FRANCE BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 74

TABLE 65 UK BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 75

TABLE 66 UK BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 75

TABLE 67 UK BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 76

TABLE 68 UK BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 76

TABLE 69 ITALY BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 77

TABLE 70 ITALY BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 77

TABLE 71 ITALY BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 78

TABLE 72 ITALY BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 78

TABLE 73 SPAIN BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 79

TABLE 74 SPAIN BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 79

TABLE 75 SPAIN BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 80

TABLE 76 SPAIN BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 80

TABLE 77 REST OF WESTERN EUROPE BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 81

TABLE 78 REST OF WESTERN EUROPE BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 81

TABLE 79 REST OF WESTERN EUROPE BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 82

TABLE 80 REST OF WESTERN EUROPE BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 82

TABLE 81 EASTERN EUROPE BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 83

TABLE 82 EASTERN EUROPE BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 83

TABLE 83 EASTERN EUROPE BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 84

TABLE 84 EASTERN EUROPE BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 84

TABLE 85 ASIA-PACIFIC BIOLOGICS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 85

TABLE 86 ASIA-PACIFIC BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 86

TABLE 87 ASIA-PACIFIC BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 86

TABLE 88 ASIA-PACIFIC BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 87

TABLE 89 ASIA-PACIFIC BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 87

TABLE 90 JAPAN BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 88

TABLE 91 JAPAN BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 88

TABLE 92 JAPAN BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 89

TABLE 93 JAPAN BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 89

TABLE 94 CHINA BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 90

TABLE 95 CHINA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 90

TABLE 96 CHINA BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 91

TABLE 97 CHINA BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 91

TABLE 98 INDIA BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 92

TABLE 99 INDIA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 92

TABLE 100 INDIA BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 93

TABLE 101 INDIA BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 93

TABLE 102 AUSTRALIA BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 94

TABLE 103 AUSTRALIA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 94

TABLE 104 AUSTRALIA BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 95

TABLE 105 AUSTRALIA BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 95

TABLE 106 SOUTH KOREA BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 96

TABLE 107 SOUTH KOREA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 96

TABLE 108 SOUTH KOREA BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 97

TABLE 109 SOUTH KOREA BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 97

TABLE 110 REST OF ASIA-PACIFIC BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 98

TABLE 111 REST OF ASIA-PACIFIC BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 98

TABLE 112 REST OF ASIA-PACIFIC BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 99

TABLE 113 REST OF ASIA-PACIFIC BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 99

TABLE 114 MIDDLE EAST & AFRICA BIOLOGICS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 100

TABLE 115 MIDDLE EAST & AFRICA BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 101

TABLE 116 MIDDLE EAST & AFRICA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 101

TABLE 117 MIDDLE EAST & AFRICA BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 102

TABLE 118 MIDDLE EAST & AFRICA BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 102

TABLE 119 MIDDLE EAST BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 103

TABLE 120 MIDDLE EAST BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 103

TABLE 121 MIDDLE EAST BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 104

TABLE 122 MIDDLE EAST BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 104

TABLE 123 AFRICA BIOLOGICS MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 105

TABLE 124 AFRICA BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY BY TYPE, 2020 TO 2027 (USD MILLION) 105

TABLE 125 AFRICA BIOLOGICS MARKET BY DISEASE INDICATION, 2020 TO 2027 (USD MILLION) 106

TABLE 126 AFRICA BIOLOGICS MARKET BY MANUFACTURING, 2020 TO 2027 (USD MILLION) 106

โ€ƒ

14 List Of Figures

FIGURE 1 MARKET STRUCTURE 16

FIGURE 2 RESEARCH PROCESS 18

FIGURE 3 TOP DOWN & BOTTOM-UP APPROACH 21

FIGURE 4 MARKET DYNAMICS: GLOBAL BIOLOGICS MARKET 23

FIGURE 5 VALUE CHAIN: GLOBAL BIOLOGICS MARKET 27

FIGURE 7 GLOBAL BIOLOGICS MARKET BY PRODUCT, 2020 & 2027 (USD MILLION) 34

FIGURE 8 GLOBAL BIOLOGICS MARKET BY DISEASE INDICATION, 2020 & 2027 (USD MILLION) 41

FIGURE 9 GLOBAL BIOLOGICS MARKET BY MANUFACTURING, 2020 & 2027 (USD MILLION) 50

FIGURE 10 GLOBAL BIOLOGICS MARKET BY REGION, 2020 & 2027 (USD MILLION) 53

FIGURE 11 AMERICAS BIOLOGICS MARKET BY REGION, 2020 (%) 54

FIGURE 12 NORTH AMERICA BIOLOGICS MARKET SHARE BY COUNTRY, 2020 (%) 57

FIGURE 13 EUROPE BIOLOGICS MARKET BY REGION, 2020 (%) 65

FIGURE 14 WESTERN EUROPE BIOLOGICS MARKET BY COUNTRY, 2020 (%) 68

FIGURE 15 ASIA-PACIFIC BIOLOGICS MARKET BY REGION, 2020 (%) 85

FIGURE 16 MIDDLE EAST & AFRICA BIOLOGICS MARKET BY REGION, 2020 (%) 100

FIGURE 17 GLOBAL BIOLOGICS MARKET, MARKET SHARE ANALYSIS 2020 (%) 108

FIGURE 18 GLOBAL BIOLOGICS MARKET COMPETITIVE LANDSCAPE (%) 109

Biologics Market

Biologics Market is projected to be worth USD 285,520.4 Million at CAGR of 10.50 % during the forecast period.

Segmentation

By Product Monoclonal Antibody Interleukins Vaccines Growth Factors Gene Therapy Others
By Disease Indication Rheumatoid Arthritis Psoriasis/Psoriatic Arthritis Cancer Diabetes Others

Key Players

  • AbbVie
  • Inc. (U.S.)
  • Pfizer Inc. (U.S.)
  • AstraZeneca (U.K.)
  • Novartis AG (Switzerland)
  • Hoffman-La Roche AG (Switzerland)
  • Bayer AG (Germany)
  • Amgen (U.S.)
  • Sanofi (France)
  • Eli Lilly and Company (U.S.)
  • GlaxoSmithKline Plc (U.K.) Celltrion Inc. (Seoul Korea) Samsung Biologics Co. Ltd. (Seoul Korea) G. Chem Ltd. (Seoul Korea)

Drivers

  • Development Of Several Biopharmaceutical Products
  • Expansion Of Manufacturing Capabilities
Speak to Analyst Request a Free Sample

Biologics Market Overview


Biologics Market is estimated to observe global market development at a 10.50% CAGR by 2030 as per a Market Research Future (MRFR) report. It is also foreseen to touch a valuation of USD 285,520.4 Million by the conclusion of the forecast period in 2030. Biologics are derived from animals, humans, and microorganisms by biotechnology tools. The drugs produced subsequently using biologics are being used to treat a range of chronic diseases. Unceasing improvement in the pharmaceutical sector is anticipated to be one of the primary factors to boost biologics' demand in the upcoming period.

COVID-19 Analysis of Biologics Market


A widespread prevalence of potentially vulnerable population groups during the COVID-19 pandemic leads regulators to consent to the continuous production of small molecule drugs than before. The industry is observing concrete plans to arrive at the next frontier, which involves continuous manufacturing for biologics, thus boosting the biologics manufacturing market. The ICH is estimated to issue strategies in 2021 for the continuous manufacturing of biologics to achieve this goal. Around 50 other national regulators have reached at least one such agreement, confirming that this technique has earned worldwide acknowledgment for small molecules. The fast-tracked approvals from the FDA for effective biologics are estimated to surge as countries race to control the pandemic's spread.


Biologics Market Dynamics


Drivers

Development Of Several Biopharmaceutical Products


The incidence of prevailing chronic diseases and the extensive healthcare financial plan of several nations is estimated to play a pivotal role in the development of the global as well as the biologics market. The Enhancements observed in the healthcare organization combined with transformations by several countries are likely to bode well for the biologics market over the forecast period. Furthermore, advances in the market for anti-inflammatory biologics are estimated to create promising advances for the overall biologics market.


Expansion Of Manufacturing Capabilities


The espousal of novel biotechnology procedures by pharmaceutical heavyweights to accelerate their production course is projected to lead to diversity in iterations of listed drugs. The innovations in biologics and negligible health effects are expected to strengthen the requirement for the biologics market size until 2023.


Opportunities


Promoted Research Into Genetics


The augmented identification of the genetic and molecular origins of any particular disease has initiated a robust expansion in the development of a variety of targeted treatments, which is expected to pick up pace in the coming period.


Challenges


High Biologics Production Costs


The elevated production costs associated with biologics production may lead to potential players delaying their plans to step into the market due to the deceleration in global biologics market.


Restrictions In Access To Capacity


Companies with lower capacities are estimated to face hindrances in accessing higher manufacturing capacity, which may lead to loss in the capitalization of lucrative opportunities that may appear in the future.


Restraints


Emergence of Biosimilars


The emergence of biosimilars is estimated to challenge the new market dynamics for biologics in the forecast period.


Biologics Market Segment Overview


The biologics market segments are as follows:


By Product


Monoclonal antibodies (mABs) are estimated to control the largest share due to the developed usage of this drug category in different therapeutic areas. The application in the treatment of terminal diseases is estimated to promote overall market growth in the forecast period.


By Disease Indication


The cancer biologics market segment is estimated to show the most promise in the development of the global market. Due to better diagnostics and accessibility to skilled professionals, the surge in cancer cases is likely to make this segment the highest consumer of biologics.


By Manufacturing


The Sourced segment is estimated to gain prominence in the global market through the forecast period. As most companies do not have advanced manufacturing capacity, sourced manufacturing such as CMOs are estimated to gain prevalence in the biologics market forecast period.


Biologics Market Regional Analysis


North American Regional Market to Lead


The North American biologics market currently shares nearly half of the worldwide biologics market due to intensifying diabetic and cancer patient bases, collective healthcare spending surge, and governmental backing for research and development. This share is estimated to intensify further in the coming years.


European Regional Market to Set Record Contribution By 2023


The national markets in the U.K. and Germany are the key contributors to the biologics market growth. Strong contenders in the regions are projected to further the regional market's expansion in the coming period.


Biologics Market- Competitive Landscape


The significant players profiled in the biologics market report are:




  • AbbVie, Inc. (U.S.),




  • Pfizer Inc. (U.S.),




  • AstraZeneca (U.K.),




  • Novartis AG (Switzerland),




  • Hoffman-La Roche AG (Switzerland),




  • Bayer AG (Germany), Amgen (U.S.), Sanofi (France),




  • Eli Lilly and Company (U.S.),




  • GlaxoSmithKline Plc (U.K.)




  • Celltrion Inc. (Seoul Korea)




  • Samsung Biologics Co. Ltd. (Seoul Korea)




  • G. Chem Ltd. (Seoul Korea)




Recent Developments


Dec 2020 South Korea's pharmaceutical sector is estimated to become progressively advanced and appealing to foreign investment 18 months into the government's recent USD 1.7bn five-year biotech plan. The nation's pharmaceutical business is now prepared to expand from its arrangements to manufacture big amounts of COVID-19 vaccine for domestic and foreign markets alike.


Nov 2020 Stelis BioSource is mounting its biologics manufacturing facility situated in India. The development is a part of the company's comprehensive investment plan, under which it previously capitalized more than USD 100m in its Bangalore facilities. The investment program will generate an international platform for vaccines, biologics, and pharmaceutical drug products. The expansion will also prime the mammalian facility with two 2,000l single-use bioreactor trains for CGMP production of mammalian drug substance.


Nov 2020 Biocon Biologics is in discussions to advance funds from ADQ, the Abu Dhabi government's autonomous wealth fund, as India's foremost biosimilar firm strengthens its manufacturing to add value to shareholders ahead of a planned IPO. The dialogs would potentially lead to the fourth consecutive capitalizing in the firm this year. The previous fund-raising round led to a pre-money equity estimation of USD 3.94 billion for the firm, planning for an initial public offering in the coming period.


Nov 2020 WuXi Biologics has endorsed various deals with clients to study antibodies for providing coronavirus treatments. The company is currently working on ten neutralizing antibodies and also one COVID-19 vaccine.


Nov 2020 Samsung Biologics, a South Korean firm, has consented to an agreement with Eli Lilly & Company to produce its tentative Covid-19 virus-neutralizing antibody. Bamlanivimab is an investigational antibody that targets the spike protein of SARS-CoV-2 and is created to constrain the virus's bond and entry into human cells. As per the contract manufacturing organization (CMO) contract, Samsung Biologics will be mass-producing Lilly's treatment for treating COVID-19 patients.


Report Overview


Segmentation Table


By Product




  • Monoclonal Antibod




  • Humanized




  • Human




  • Chimeric




  • Murine




  • Interleukins




  • Vaccines




  • Growth Factors




  • Gene Therapy




  • Others




By Disease Indication




  • Rheumatoid Arthritis




  • Psoriasis/Psoriatic Arthritis




  • Ankylosing Spondylitis




  • Juvenile Idiopathic Arthropathy




  • Ulcerative Colitis




  • Crohn's Disease




  • Cardiovascular Disease




  • Cancer




  • Diabetes




  • Others




By Manufacturing




  • In-house




  • Outsourced




By Region


Americas




  • North America




  • The U.S.




  • Canada




  • South America




Europe




  • Western Europe




    • Germany




    • France




    • Spain




    • Italy




    • Rest of Western Europe






  • Eastern Europe




Asia Pacific




  • Australia




  • South Korea




  • India




  • Japan




  • China




  • Rest of Asia Pacific




The Middle East & Africa




  • The Middle East




  • Africa




The report encompasses important insights attained by our analysts through an amalgamation of primary and secondary research. The biologics market growth is examined with meticulous detail and segmented on the basis of product, manufacturing, disease indication, and region. New product unveilings and biologics global biologics market opportunities and strategies of pharmaceutical firms, as well as their effectiveness and functioning, are reviewed extensively within the biologics market report.



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 285,520.4 Million
  CAGR   2020-2030: 10.50%
  Base Year   2020
  Forecast Period   2020
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Product, Disease Indication, Manufacturing
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   AbbVie, Inc. (U.S.), Pfizer Inc. (U.S.), AstraZeneca (U.K.), Novartis AG (Switzerland), Hoffman-La Roche AG (Switzerland), Bayer AG (Germany), Amgen (U.S.), Sanofi (France), Eli Lilly and Company (U.S.), GlaxoSmithKline Plc (U.K.) Celltrion Inc. (Seoul Korea) Samsung Biologics Co. Ltd. (Seoul Korea) G. Chem Ltd. (Seoul Korea)
  Key Market Opportunities   Promoted Research Into Genetics
  Key Market Drivers

  • Development Of Several Biopharmaceutical Products
  • Expansion Of Manufacturing Capabilities


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The Biologics Market is growing at a 10.50% by 2030.

    AbbVie, Inc. (U.S.), Pfizer Inc. (U.S.), AstraZeneca (U.K.), Novartis AG (Switzerland), Hoffman-La Roche AG (Switzerland), Bayer AG (Germany), Amgen (U.S.), Sanofi (France), Eli Lilly and Company (U.S.), GlaxoSmithKline Plc (U.K.) Celltrion Inc. (Seoul Korea) Samsung Biologics Co. Ltd. (Seoul Korea) G. Chem Ltd. (Seoul Korea)

    Global Biologics Market is segmented based on Product, Manufacturing, And Disease Indication.

    The Major driver of Biologics Market is Development Of Several Biopharmaceutical Products.

    Global Biologics Market: Competitive Landscape


    The prominent players in the Global Biologics Market are F. Hoffmann-La Roche AG, AbbVie Inc., Pfizer Inc., Amgen Inc., and GlaxoSmithKline plc, Hoffmann-La Roche AG is a biotech organization, with genuinely differentiated solutions in oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. The company is dedicated to developing innovative diagnostic tests and medicines which will help the patients and the world.


    Pfizer Inc. is a leading research-based biopharmaceutical company that applies science and resources to provide inventive treatments that extend and significantly improve the lives. Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments, namely, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).


    The Global Biologics Market is characterized by the presence of global, regional, and local vendors. The market is highly competitive with all players competing to gain the market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront the market growth. The vendors compete based on cost, quality, and reliability. It is decisive for vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive market environment.


    The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, the vendors should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional and foreign players with small market shares also have a presence. It has also been forecast that the improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new products.


    Through extensive research, it is found out that the market players have adopted the strategy of mergers and acquisitions and launching new products in the market


    Many leading players are focusing on the American and European markets owing to well-established markets, huge patient population, and high healthcare expenditures. These players have expanded their market in other regions as well. Major companies have a huge brand identity and product portfolio. These companies have adopted the fundamental strategy of mergers and acquisitions and product launches to gain the market.